Treatment of osteoarthritis with incretin hormones or analogues thereof

Patent metadata

Field	Value
Publication number	US-9592272-B2
Application number	US-201314424475-A
Country	US
Kind code	B2
Filing date	Aug 29, 2013
Priority date	Aug 30, 2012
Publication date	Mar 14, 2017
Grant date	Mar 14, 2017

Abstract

The present invention relates to the use of the incretin hormones glucagon-like peptide-1 or GLP-1 and glucose-dependent insulinotropic polypeptide or GIP, or of analogs thereof, in particular the analogs resistant to dipeptidyl peptidase IV, in the treatment of osteoarthritis, in particular for inhibiting or slowing down cartilage destruction.

First claim

The invention claimed is:

1. A method of treating osteoarthritis comprising administering intra-articularly a therapeutically effective dose of a peptide selected from the group consisting of a glucagon-like peptide 1 (GLP-1), a gastric inhibitory peptide (GIP) and analogues thereof resistant to dipeptidyl peptidase IV (DPP-IV) to a subject having osteoarthritis, wherein the therapeutically effective dose of the peptide or the analogue thereof inhibits or slows down the arthritic cartilage destruction.

2. The method according to claim 1 , wherein the peptide comprises a sequence selected from the group consisting of SEQ ID NOs: 1 to 6.

3. The method according to claim 2 , wherein the peptide is selected from the group consisting of the SEQ ID NO: 4 and SEQ ID NO: 3.

4. The method according to claim 2 , wherein the peptide is SEQ ID NO: 6.

5. The method according to claim 1 , wherein the peptide is an analogue of the GLP-1 or GIP and is resistant to DPP-IV.

6. The method according to claim 1 , wherein the peptide is an analogue of the GLP-1 and is resistant to DPP-IV.

7. The method according to claim 6 , wherein the peptide is selected from the group consisting of exenatide, liraglutide, exendin-4, albiglutide, taspoglutide, lixisenatide, dulaglutide (LY2189265), LY315902, LY2199265, LY2428757, semaglutide (NN9535), CJC-1131, CJC-1134 and ZP10.

8. The method according to claim 7 , wherein the peptide is selected from the group consisting of exenatide and liraglutide.

9. The method according to claim 1 , said method comprising the administration of the peptide selected from the group consisting of the GLP-1, the GIP and the analogues thereof resistant to dipeptidyl peptidase IV (DPP-IV) in combination with one or more other active substances selected from the group consisting of analgesics, non-steroidal anti-inflammatories, steroidal anti-inflammatories and slow-acting anti-arthritic agents.

10. The method according to claim 9 , wherein the peptide and said other active substance(s) are administered simultaneously.

11. The method according to claim 9 , wherein the peptide and said other active substance(s) are administered sequentially.

12. The method according to claim 1 , wherein the peptide is administered in combination with local treatments for osteoarthritis.

13. The method according to claim 1 , wherein said method comprises the intra-articular administration of a pharmaceutical composition comprising one or more peptides selected from the group consisting of the GLP-1, the GIP and the analogues thereof resistant to dipeptidyl peptidase IV (DPP-IV) and a pharmaceutically acceptable support and/or excipient.

14. The method according to claim 13 , wherein said pharmaceutical composition comprises one or more other active substances selected from the group consisting of analgesics, non-steroidal anti-inflammatories, steroidal anti-inflammatories and slow-acting anti-arthritic agents.

Assignees

• Univ Pierre Et Marie Curie Paris 6
• Assist Publique—Hopitaux De Paris
• Assist Publique—Hôpitaux De Paris

Inventors

• Berenbaum Francis
• Bougault Carole
• Attali Claire

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• A61K38/26

  Glucagons · CPC title

• A61K38/22 Primary

  Hormones (derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin A61K38/33, e.g. corticotropin A61K38/35) · CPC title

• A61P19/02

  for joint disorders, e.g. arthritis, arthrosis · CPC title